Pathstone Holdings, LLC Athira Pharma, Inc. Transaction History

Pathstone Holdings, LLC

  • $25.6 Billion
  • Q3 2025

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 14, 2025
SELL
$0.42 - $0.8 $50,370 - $95,944
-119,930 Reduced 24.37%
372,196 $219,000
Q3 2024

Nov 07, 2024
SELL
$0.42 - $3.43 $42 - $343
-100 Reduced 0.02%
492,126 $221,000
Q1 2024

May 13, 2024
BUY
$2.24 - $4.15 $268,643 - $497,709
119,930 Added 32.21%
492,226 $1.35 Million
Q4 2023

Feb 14, 2024
BUY
$1.39 - $2.46 $517,491 - $915,848
372,296 New
372,296 $904,000

About Athira Pharma, Inc.

ATHA Quotes by TradingView
  • Ticker ATHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,817,700
  • Market Cap $174M
  • Description
  • Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical tri...
More about ATHA
Track This Portfolio

Track Pathstone Holdings, LLC Portfolio

Follow Pathstone Holdings, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pathstone Holdings, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pathstone Holdings, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email